Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 263

Similar articles for PubMed (Select 24084459)

1.

Molecular characterization of Ph-negative myeloproliferative neoplasms in Ukraine.

Mishcheniuk OY, Kostukevich OM, Dmytrenko IV, Sholoyko VV, Prokopenko IM, Martina ZV, Pilipenko GV, Klymenko SV.

Exp Oncol. 2013 Sep;35(3):202-6.

PMID:
24084459
2.

JAK2 V617F, MPL, and CALR Mutations in Korean Patients with Essential Thrombocythemia and Primary Myelofibrosis.

Kim BH, Cho YU, Bae MH, Jang S, Seo EJ, Chi HS, Choi Y, Kim DY, Lee JH, Lee JH, Lee KH, Park YM, Lee JK, Park CJ.

J Korean Med Sci. 2015 Jul;30(7):882-8. doi: 10.3346/jkms.2015.30.7.882. Epub 2015 Jun 10.

3.
4.

Dynamics of JAK2 V617F allele burden of CD34+ haematopoietic progenitor cells in patients treated with ruxolitinib.

Angona A, Alvarez-Larrán A, Bellosillo B, Longarón R, Fernández-Rodríguez C, Besses C.

Br J Haematol. 2015 Jun 26. doi: 10.1111/bjh.13535. [Epub ahead of print] No abstract available.

PMID:
26115187
5.

Myeloproliferative neoplasm patient symptom burden and quality of life: Evidence of significant impairment compared to controls.

Anderson LA, James G, Duncombe AS, Mesa R, Scherber R, Dueck AC, de Vocht F, Clarke M, McMullin MF.

Am J Hematol. 2015 Jun 25. doi: 10.1002/ajh.24098. [Epub ahead of print]

PMID:
26113113
6.

Prognostic significance of ASXL1, JAK2V617F mutations and JAK2V617F allele burden in Philadelphia-negative myeloproliferative neoplasms.

Yonal-Hindilerden I, Daglar-Aday A, Akadam-Teker B, Yilmaz C, Nalcaci M, Yavuz AS, Sargin D.

J Blood Med. 2015 Jun 1;6:157-75. doi: 10.2147/JBM.S78826. eCollection 2015.

7.

The Prevalence of JAK2, MPL, and CALR Mutations in Chinese Patients With BCR-ABL1-Negative Myeloproliferative Neoplasms.

Lin Y, Liu E, Sun Q, Ma J, Li Q, Cao Z, Wang J, Jia Y, Zhang H, Song Z, Ai X, Shi L, Feng X, Li C, Wang J, Ru K.

Am J Clin Pathol. 2015 Jul;144(1):165-71. doi: 10.1309/AJCPALP51XDIXDDV.

PMID:
26071474
8.

Impact of JAK2(V617F) mutation status on treatment response to anagrelide in essential thrombocythemia: an observational, hypothesis-generating study.

Cascavilla N, De Stefano V, Pane F, Pancrazzi A, Iurlo A, Gobbi M, Palandri F, Specchia G, Liberati AM, D'Adda M, Gaidano G, Fjerza R, Achenbach H, Smith J, Wilde P, Vannucchi AM.

Drug Des Devel Ther. 2015 May 18;9:2687-94. doi: 10.2147/DDDT.S79576. eCollection 2015.

9.

Genomic and Clinicopathologic Features of Primary Myelofibrosis With Isolated 13q Deletion.

Mehrotra M, Patel KP, Chen T, Miranda RN, Wang Y, Zuo Z, Muddasani R, Mishra BM, Abraham R, Luthra R, Lu G.

Clin Lymphoma Myeloma Leuk. 2015 Apr 3. pii: S2152-2650(15)00135-4. doi: 10.1016/j.clml.2015.03.018. [Epub ahead of print]

PMID:
26027540
10.

KIT D816V and JAK2 V617F mutations are seen recurrently in hypereosinophilia of unknown significance.

Schwaab J, Umbach R, Metzgeroth G, Naumann N, Jawhar M, Sotlar K, Horny HP, Gaiser T, Hofmann WK, Schnittger S, Cross NC, Fabarius A, Reiter A.

Am J Hematol. 2015 May 28. doi: 10.1002/ajh.24075. [Epub ahead of print]

PMID:
26017288
11.

Association of lymphoid malignancies and Philadelphia-chromosome negative myeloproliferative neoplasms: Clinical characteristics, therapy and outcome.

Masarova L, Newberry KJ, Pierce SA, Estrov Z, Cortes JE, Kantarjian HM, Verstovsek S.

Leuk Res. 2015 May 12. pii: S0145-2126(15)00132-0. doi: 10.1016/j.leukres.2015.05.002. [Epub ahead of print]

PMID:
26012362
12.

Current therapies and their indications for the Philadelphia-negative myeloproliferative neoplasms.

Kiladjian JJ.

Am Soc Clin Oncol Educ Book. 2015;35:e389-96. doi: 10.14694/EdBook_AM.2015.35.e389.

13.

From Philadelphia-Negative to JAK2-Positive: Effect of Genetic Discovery on Risk Stratification and Management.

Pemmaraju N, Moliterno AR.

Am Soc Clin Oncol Educ Book. 2015;35:139-45. doi: 10.14694/EdBook_AM.2015.35.139.

14.

Janus kinase inhibitors: jackpot or potluck?

Pavithran K, Pande SB.

Oncol Rev. 2012 Jun 20;6(1):e13. doi: 10.4081/oncol.2012.e13. eCollection 2012 Mar 5. Review.

15.

Loss of S-100-positive Schwann cells is a feature of JAK2 V617F-positive myeloproliferative neoplasm.

Bihari C, Rastogi A, Saxena P, Kumar A.

Ann Hematol. 2015 Aug;94(8):1427-9. doi: 10.1007/s00277-015-2396-x. Epub 2015 May 14. No abstract available.

PMID:
25968911
16.

Changing incidence of myeloproliferative neoplasms: trends and subgroup risk profiles in the USA, 1973-2011.

Deadmond MA, Smith-Gagen JA.

J Cancer Res Clin Oncol. 2015 May 13. [Epub ahead of print]

PMID:
25968903
17.

[Status and perspectives on chronic myeloproliferative neoplasm treatment].

Ocias LF, Holmström MO, Riley CH, Andersen CL, Rønnov-Jessen D, Starklint J, Frederiksen M, Steffensen MS, Bjerrum OW, Farmer S, Mourits-Andersen T, Hasselbalch HC, Larsen TS.

Ugeskr Laeger. 2015 May 4;177(19). pii: V12140652. Danish.

PMID:
25967090
18.

JAK2 46/1 haplotype is associated with JAK2 V617F - positive myeloproliferative neoplasms in Brazilian patients.

Macedo LC, Santos BC, Pagliarini-E-Silva S, Pagnano KB, Rodrigues C, Quintero FC, Ferreira ME, Baraldi EC, Ambrosio-Albuquerque EP, Sell AM, Visentainer JE.

Int J Lab Hematol. 2015 May 11. doi: 10.1111/ijlh.12380. [Epub ahead of print]

PMID:
25959311
19.

Molecular diagnostics of myeloproliferative neoplasms.

Langabeer SE, Andrikovics H, Asp J, Bellosillo B, Carillo S, Haslam K, Kjaer L, Lippert E, Mansier O, Oppliger Leibundgut E, Percy MJ, Porret N, Palmqvist L, Schwarz J, McMullin MF, Schnittger S, Pallisgaard N, Hermouet S; MPN&MPNr-EuroNet.

Eur J Haematol. 2015 May 7. doi: 10.1111/ejh.12578. [Epub ahead of print]

PMID:
25951317
20.

Analysis of phenotype and outcome in essential thrombocythemia with CALR or JAK2 mutations.

Al Assaf C, Van Obbergh F, Billiet J, Lierman E, Devos T, Graux C, Hervent AS, Emmerechts J, Tousseyn T, De Paepe P, Papadopoulos P, Michaux L, Vandenberghe P.

Haematologica. 2015 Jul;100(7):893-7. doi: 10.3324/haematol.2014.118299. Epub 2015 May 1.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk